Document Detail


Observations on praziquantel against Schistosoma haematobium.
MedLine Citation:
PMID:  7195249     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide) in single oral doses between 15 and 50 mg/kg given to subjects of all ages with Schistosoma haematobium infections produced few side effects even at the higher doses. Parasitological results were as follows: a) 15--20 mg/kg were too low to consistently give a favourable parasitological response. b) 21--25 mg/kg cured a high proportion of cases but because of poor response in some persons with high pretreatment egg loads, this dose range is not recommended. c) Doses of 45--50 mg/kg did not appear to improve efficacy when compared with 30--40 mg/kg. 2. Praziquantel was highly effective and had low toxicity in a controlled trial in schoolchildren. There was no significant difference in efficacy between two single dose regimens (30 and 40 mg/kg) and a split dose of 2x20 mg/kg given 4 h apart. In long-term follow-up examination no viable eggs were being excreted in 45 of 53 (84.9%) and 37 of 50 (74%) subjects examined 1 and 2 years, respectively, after treatment. 3. 16 persons excreting viable eggs 6 months after treatment were retreated with 35 mg/kg. Six months later 14 of the 16 (87.5%) were cured.
Authors:
J E McMahon
Related Documents :
15597709 - Effect of artemether on schistosoma mansoni: dose-efficacy relationship, and changes in...
6118029 - The long term effects of repeated diethylcarbamazine administration with special refere...
10870669 - Study of immunological and virological parameters during thalidomide treatment of siv-i...
1878259 - Potentials of shigella flexneri y strain tsf21 as a candidate vaccine against shigellos...
8369939 - Prophylactic use of cefuroxime in biliary tract surgery: randomized controlled trial of...
2167039 - In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is t...
20165849 - A phase i study of obatoclax mesylate, a bcl-2 antagonist, plus topotecan in solid tumo...
23659169 - A new flavonoid c-glycoside from solanum elaeagnifolium with hepatoprotective and curat...
14675099 - Safety of plasmin in the setting of concomitant aspirin and heparin administration in a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  31     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1981  
Date Detail:
Created Date:  1981-07-20     Completed Date:  1981-07-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  579-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Child
Humans
Isoquinolines / therapeutic use*
Praziquantel / adverse effects,  therapeutic use*
Schistosoma haematobium
Schistosomiasis / drug therapy*
Chemical
Reg. No./Substance:
0/Isoquinolines; 55268-74-1/Praziquantel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal
Next Document:  Epidemiological study of foci of S. intercalatum schistosomiasis in Eseka and Edea (Cameroon). Effec...